Eculizumab — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

5 Recruiting

5 Completed trials

10 Sponsors

17 Countries

Phase III

Phase I (FiH)

Phase III: 6 Phase II/III: 1 Phase II: 1 Phase I/II: 1 Phase I (FiH): 2

Oversight events:

11 temporary halts 1 urgent safety measure 1 unexpected event 1 corrective measure across 5 trials

View oversight register →

Indications tested

Duchenne muscular dystrophy 2 Atypical haemolytic uraemic syndrome 1 Paroxysmal nocturnal haemoglobinuria 1 Myasthenia gravis 1 Gaucher's disease type I 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 2 Alexion Pharmaceuticals Inc. 1 Assistance Publique Hopitaux De Paris 1 Genethon 1 Kyverna Therapeutics Inc. 1 Pfizer Inc. 1 Prevail Therapeutics Inc. 1 Regeneron Pharmaceuticals Inc. 1 Rocket Pharmaceuticals Inc. 1 Ultragenyx Pharmaceutical Inc. 1

All trials

11 total

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults with Wilson Disease”. Recruiting

2022-502873-40-00 Phase I (FiH) 5 countries Ultragenyx Pharmaceutical Inc.
Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients with Danon Disease Recruiting

2023-506480-34-00 Phase II 2 countries Rocket Pharmaceuticals Inc.
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Generalized Myasthenia Gravis Recruiting

2023-509892-17-00 Phase II/III 1 country Kyverna Therapeutics Inc.
Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) Recruiting

2024-516402-32-00 Phase III 1 country Assistance Publique Hopitaux De Paris
A clinical study in 3 parts with a microdystrophin (called GNT0004), a new gene therapy in boys with Duchenne disease who can still walk. Th… Recruiting

2023-505187-11-00 Phase I (FiH) 3 countries Genethon
A PHASE 3, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF PF-06939926 IN DMD Ended

2023-508510-42-00 Phase III 5 countries Pfizer Inc.
A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended

2023-504867-18-00 Phase III 6 countries Alexion Pharmaceuticals Inc.
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients with Paroxysmal Nocturnal… Ended

2023-509657-31-00 Phase III 6 countries Regeneron Pharmaceuticals Inc.
A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemog… Ended

2023-506498-36-00 Phase III 9 countries F. Hoffmann-La Roche AG
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo… Ended

2023-506526-37-00 Phase III 13 countries F. Hoffmann-La Roche AG
A dose finding study of LY3884961 in patients with Gaucher disease Halted

2022-500281-10-02 Phase I/II 2 countries Prevail Therapeutics Inc.

Showing 1–11 of 11 trials

← All drugs A–Z